Mirae Asset Global Investments Co. Ltd. Has $686,000 Stock Holdings in Morphic Holding, Inc. (NASDAQ:MORF)

Mirae Asset Global Investments Co. Ltd. raised its position in Morphic Holding, Inc. (NASDAQ:MORF) by 12.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,758 shares of the company’s stock after buying an additional 2,546 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Morphic were worth $686,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MORF. SG Americas Securities LLC grew its holdings in Morphic by 1,041.3% in the 3rd quarter. SG Americas Securities LLC now owns 22,015 shares of the company’s stock valued at $504,000 after buying an additional 20,086 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Morphic by 12.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 123,925 shares of the company’s stock valued at $2,839,000 after buying an additional 13,686 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Morphic by 38.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,182 shares of the company’s stock valued at $142,000 after buying an additional 1,705 shares in the last quarter. TD Asset Management Inc grew its holdings in Morphic by 38.5% in the 3rd quarter. TD Asset Management Inc now owns 93,112 shares of the company’s stock valued at $2,133,000 after buying an additional 25,895 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Morphic by 106.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,238 shares of the company’s stock worth $28,000 after purchasing an additional 638 shares in the last quarter. 94.25% of the stock is owned by institutional investors and hedge funds.

Morphic Stock Performance

MORF opened at $27.69 on Thursday. The firm has a market cap of $1.39 billion, a P/E ratio of -7.93 and a beta of 1.42. Morphic Holding, Inc. has a 52-week low of $19.34 and a 52-week high of $63.08. The business’s fifty day moving average is $33.55 and its 200-day moving average is $29.01.

Morphic (NASDAQ:MORF) last released its earnings results on Thursday, February 22nd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.05). On average, research analysts predict that Morphic Holding, Inc. will post -3.9 earnings per share for the current fiscal year.

About Morphic

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.